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SShould endobronchial ultrasonography be part of the thoracic
surgeon’s armamentarium?
Sebastien Gilbert, MD,a David O. Wilson, MD, MPH,b Neil A. Christie, MD,a James D. Luketich, MD,a Rodney J. Landreneau, MD,a
John M. Close, MS, PMSD,c and Matthew J. Schuchert, MDa
Objective: The study objective was to determine the clinical usefulness and accuracy of endobronchial ultra-
sound-guided needle aspiration of mediastinal and hilar lymph nodes.
Methods: A retrospective analysis of a thoracic surgery unit’s experience was performed.
Results: In a period of 19 months, 75 patients underwent the procedure (mean age ¼ 65.5  1.6 years; male to
female ¼ 2:1) most commonly for mediastinal lymphadenopathy in the setting of diagnosed or suspected lung
cancer. It was diagnostic in 68.9% after rapid on-site evaluation and 74.3% after final cytologic examination.
The rapid on-site evaluation and final cytology results were discordant in 16.2% (P< .001). In 50 cases, the
needle aspirate cytology could be compared with pathology results. The sensitivity and specificity for the
diagnosis of cancer were 85% and 100%, respectively. The false-negative rate endobronchial ultrasound
cytology was 8.1%. Mediastinal lymph node station 7 was most commonly biopsied. The stations with the
highest diagnostic yield were: 11R, 3, 10L, and 7. Of the patients with a positive positron emission tomogra-
phy scan with suspected clinical stage III lung cancer, cancer was downstaged in 40% after endobronchial
ultrasound.
Conclusion: Endobronchial ultrasound-guided needle aspiration is a clinically useful minimally invasive option
for lung cancer staging and evaluation of mediastinal lymphadenopathy. The procedure should be considered
complementary to mediastinoscopy.
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TTo date, thoracic surgeons have played an important role in
the evaluation of mediastinal lymphadenopathy and the me-
diastinal staging of lung cancer. This is in large part due to
their ability to safely and reliably perform mediastinoscopy.
Endobronchial ultrasound-guided transbronchial needle as-
piration (EBUS-TBNA) is a relatively new procedure that
is often associated with the emerging field of interventional
bronchoscopy. Such technology may result in significant
changes to the established approaches to diagnosis and man-
agement of thoracic diseases. As more efficacy data become
available, EBUS may assume an increasingly important role
in the practice of thoracic surgery. Through learning and
adaptation, thoracic surgeons will likely continue to expand
their therapeutic armamentarium while playing a key role in
critically appraising new technology. Our main objectives
were to successfully integrate EBUS into our minimally
invasive surgical practice and obtain data on its clinical
usefulness and accuracy for the evaluation of mediastinal
lymph nodes.
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Patients and Personnel
With approval from the institutional review board, a retrospective re-
view of all patients who underwent EBUS-TBNA from October 2006 to
April 2008 was completed. Completion of a continuing medical educa-
tion-approved EBUS course and 5 proctored cases were required to be
granted privileges to perform the procedure independently. On-site train-
ing was provided to the technicians, therapists, nurses, and doctors in-
volved.
Endobronchial Ultrasound Procedure
The technique and equipment necessary to perform EBUS-TBNA have
already been described extensively.1 Briefly, procedures were performed ei-
ther transorally with topical anesthesia and monitored intravenous sedation
or under general anesthesia with endotracheal intubation. The instrumenta-
tion used was manufactured by Olympus (Center Valley, Pa) and included
the Evis Exera ultrasonic bronchoscope model BF-UC160F-OL8, the Evis
Exera II video processor model CV-180, the Evis Exera II xenon light
source model CLV-80, the EUS Exera CLA processor model EU-C60,
and 22-gauge aspiration needles with syringe model NA-201SX-4022-A.
During ultrasound examination of a lymph node station, the largest identi-
fied lymph node amenable to needle puncture was biopsied. A different as-
piration needle was used at each lymph node station to avoid potential
specimen contamination. All procedures were performed with a cytologist
immediately available for rapid on-site evaluation (ROSE) of transbronchial
needle aspirates. ROSE was performed on the first specimen retrieved from
the aspiration needle after it had been air-dried and stained with Dif-Quick
(American Scientific Products, McGaw Park, Ill). Another slide was pre-
pared from the same initial specimen but was fixed in alcohol and processed
at a later time using Papanicolaou staining. The remainder of the specimen
was retrieved from the needle by reinserting the guide wire and flushing with
preservation solution. It was later centrifuged, and the solid component was
embedded in paraffin and processed using histology and immunohisto-
chemistry techniques (eg, cytokeratin-7, cytokeratin-20, and thyroid tran-
scription factor-1).
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CT ¼ computed tomography
EBUS ¼ endobronchial ultrasound-guided
transbronchial needle aspiration
PET ¼ positron emission tomography
ROSE ¼ rapid on-site evaluation
Interpretation of Cytology Results
As determined by the University of Pittsburgh’s pathology department,
nongynecologic cytology diagnostic categories included negative for ma-
lignant cells, atypical cells present, suspicious for malignant cells, and
positive for malignant cells. The final cytology report, which became
available a few days after the procedure, was reviewed and results of
each nodal station biopsy were classified as positive, negative, or nondiag-
nostic. A result was considered positive only when the cytologic diagnosis
was ‘‘positive for malignant cells.’’ The results were classified as negative
when the specimen was ‘‘negative for malignant cells’’ and the amount of
lymphocytes was deemed adequate by the cytologist. All other final cytol-
ogy results were classified as nondiagnostic. The EBUS-TBNA results
were labeled diagnostic if they were either positive or negative. Mediasti-
noscopy, mediastinal lymph node sampling or dissection, and confirma-
tory immunohistochemistry panel on a positive EBUS specimen were
considered acceptable reference pathologic tests to validate EBUS cytol-
ogy results.
Statistics
Continuous variables are expressed as the mean value standard error of
the mean. All tests of significance were 2-sided. Discrete variables were an-
alyzed for statistically significant differences using the Pearson chi-squared
method, and continuous variables were analyzed with the independent sam-
ples Student t test. Statistical calculations were performed using the Statis-
tical Package for the Social Sciences (version 15, SPPS Inc, Chicago, Ill).
RESULTS
Patients
From October 2006 to April 2008 (19 months), EBUS-
TBNA was attempted in 76 patients and completed in 75 pa-
tients. One patient could not tolerate the procedure because
of persistent severe cough despite sedation and topical anes-
thesia. The procedure was performed under sedation in
38.7% of cases and under general anesthesia with endotra-
cheal intubation in the remainder. The procedures were per-
formed by 4 thoracic surgeons (n ¼ 59; 78.7%) and 1
pulmonologist (n ¼ 16; 21.3%). No operator had previous
clinical experience with EBUS. There were 50 men
(66.7%) and 25 women (33.3%) aged 65.5  1.6 years
(range ¼ 24–87 years). Sixteen patients (21.1%) had previ-
ous major pulmonary resection, and 4 patients (5.2%) had
a previous mediastinoscopy. Pre-procedure diagnoses in-
cluded lung cancer (n ¼ 25; 33.3%), lung mass (n ¼ 24;
32%), mediastinal lymphadenopathy (lymph node short
axis>1 cm) (n¼ 12; 16%), malignancy other than primary
lung cancer (n ¼ 12; 16%), and other (n ¼ 2; 2.7%). The
indications to perform EBUS-TBNA were mediastinal
lymphadenopathy (n ¼ 52; 69.3%), positive mediastinal
or hilar lymph node(s) on positron emission tomography
(PET) scan without lymphadenopathy (n¼ 16; 21.4%), me-
diastinal staging (ie, no lymphadenopathy and negative PET
scan) (n ¼ 6; 8%), and other (n ¼ 1; 1.3%). There were no
complications, and all patients were discharged within 24
hours of the procedure (98.7% on the same day).
PET/computed tomography (CT) scans were obtained be-
fore EBUS-TBNA in 70.6% (n ¼ 53), and 81.1% of the
scans (n ¼ 43) were positive in mediastinal or hilar lymph
nodes. In patients with a negative PET scan (n ¼ 10),
EBUS-TBNA was negative in 7 and nondiagnostic in 3. Af-
ter subsequent pathologic testing (n¼ 8), EBUS-TBNA was
positive for cancer in 1 of the patients with a negative PET
scan. Of the patients with a positive PET scan (n ¼ 43),
EBUS-TBNA was positive for cancer in 13 (30.2%), nega-
tive in 16 (37.2%), and nondiagnostic in 14 (32.6%). Path-
ologic testing was available in 29 patients with positive PET
scans; of these, 15 (34.9%; 15/43) were positive for cancer
and 14 (32.6%; 14/43) were negative. On the basis of a pos-
itive mediastinal PET scan, clinical stage III lung cancer was
suspected in 20 patients with no history of malignancy. In
these patients, EBUS-TBNA was negative in 10 (50%), pos-
itive in 6 (30%), and nondiagnostic in 4 (20%). Of the 10
patients in whom EBUS was negative, 2 had positive
mediastinal lymph nodes after mediastinoscopy.
Lymph Node Stations
The number of lymph node stations sampled was 1 in
56% (n ¼ 42), 2 in 24% (n ¼ 18), 3 in 18.7% (n ¼ 14),
and 4 in 1.3% (n ¼ 1). The lymph node stations sampled
were station 7 (n ¼ 42; 56%), station 4R (n ¼ 29;
38.7%), station 10R (n ¼ 20; 26.7%), station 4L (n ¼ 15;
20%), station 10L (n ¼ 7; 9.3%), station 3 (n ¼ 7;
9.3%), station 11R (n ¼ 4; 5.3%), and station 11L (n ¼
1; 1.3%). Stations 2R and 2L were not sampled in any of
the patients. Table 1 summarizes the diagnostic yield at me-
diastinal stations that were sampled in 10 patients or more.
The concordance column reflects the proportion of patients
in whom the results were the same on ROSE and final
EBUS cytology. The overall mean number of needle passes
used to sample lymph nodes was 2.1 0.1 (range, 1–6). The
diagnostic yield ranged from 58.6% to 100%, and the sta-
tions with the highest yields were 11R, 3, 10L, and 7. For
all the sampled stations, there was complete agreement be-
tween ROSE and final cytology when the lymph nodes
were positive for cancer. When the ROSE was negative, cy-
tology results were concordant in 85.7% to 100%. In the
most commonly sampled lymph node stations (Table 1), fi-
nal cytologic examination yielded a diagnosis in 12.5% to
50% of patients in whom ROSE was deemed nondiagnostic.
At the time of final cytologic examination, the cytopatholo-
gist has access to additional biopsy material in the form of
a slide smear stained with the Papanicolaou method and
cell block preparations from centrifuged biopsy material.
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EBUS cytology Concordanceb
Station na Needle passes (mean) Diagnostic ND ROSE Positive ROSE Negative ROSE ND
4R 29 2.3  0.2 62.1% (18) 38.9% (11) 100% 92.9% 75%
4L 15 2.1  0.3 73.3% (11) 26.7% (4) 100% 100% 50%
7 41 2.2  0.2 78% (32) 22% (9) 100% 85.7% 53.3%
10R 20 2.0  0.3 60% (12) 40% (8) 100% 100% 87.5%
EBUS, Endobronchial ultrasound; ROSE, rapid on-site evaluation; ND, nondiagnostic. aNumber of patients in whom lymph node station was sampled. bRepresents the proportion of
patients in whom ROSE results were the same as final EBUS cytology results.G
T
SThis may explain the observed difference in diagnostic yield
between ROSE and final cytology.
Diagnostic Performance
ROSE results were recorded in 74 patients and compared
with final cytology results. The ROSE and final cytology re-
sults were different in 16.2% of patients (P< .001). It
should be noted that 30.4% of nondiagnostic ROSE results
were eventually found to be negative (17.4%) or positive for
cancer (13%) after final EBUS cytologic evaluation. In the
group with negative ROSE results, 92.9% ended up nega-
tive after final cytology. All patients with positive results
for cancer after ROSE also had positive results for cancer
on final cytology (ie, 100% correlation). In the 3 patients
(4.1%) in whom ROSE showed atypical cells, the cytology
results were evenly distributed between nondiagnostic, neg-
ative, and positive for cancer. Overall, EBUS-TBNA was
diagnostic in 68.9% after ROSE and 74.3% after final cyto-
logic evaluation.
In two thirds of patients (n ¼ 50), the results of EBUS-
TBNA could be compared with mediastinoscopy (n ¼ 34;
45.3%), immunohistochemistry (n ¼ 11; 14.7%), or intrao-
perative mediastinal lymph node sampling (n¼ 5; 6.7%). In
the remaining 25 patients, additional biopsies were not ob-
tained after EBUS for the following reasons: single or mul-
tiple lymph node stations found positive for cancer (n ¼ 5;
20%), specific benign diagnosis obtained (eg, sarcoidosis)
(n¼ 5; 20%), not a surgical candidate or declined additional
procedures (n¼ 4; 16%), previous mediastinoscopy (n¼ 4;
16%), abnormal lymph node not accessible by mediastino-
scopy (n ¼ 2; 8%), and other (n ¼ 5; 20%). When the
EBUS cytology was nondiagnostic (n ¼ 13; 24%), the pa-
thology was benign in 61.5% (n ¼ 8) and malignant in
38.5% (n ¼ 5). Three of 18 patients (16.6%) with benign
cytology were eventually found to have cancer. In all pa-
tients in whom EBUS-TBNA cytology was positive for can-
cer, the pathologic testing was also positive for cancer. More
specifically the cytologic diagnosis was correct in 90% of
non–small cell lung cancers, 100% of small cell lung can-
cers and metastatic cancers from a primary other than the
lung, and 50% of sarcoidosis cases. In the subgroup of
patients with a diagnostic EBUS-TBNA (n ¼ 37), the sensi-
tivity, specificity, positive predictive value, and negative
predictive value for the detection of cancer were 85%,
100%, 100%, and 85%, respectively. The false-negative
rate of EBUS-TBNA cytology was 8.1%.
Diagnostic Failures
The patient’s diagnosis or the indication to perform
EBUS-TBNA did not have a significant influence on the
overall diagnostic success rate. The presence or absence of
lymphadenopathy on CT scan and the PET findings (posi-
tive or negative), analyzed alone or in all possible com-
binations, did not influence the probability of obtaining
diagnostic cytology. There was no significant difference in
the average number of lymph node stations biopsied be-
tween the diagnostic and nondiagnostic EBUS cases. Over-
all, there was no threshold number of procedures after which
the diagnostic rate improved. This was also true for 2 of the
operators who each performed more than 20 procedures. The
probability of failure to obtain a tissue diagnosis was also
independent of the operator’s qualifications (surgeon vs
pulmonologist).
DISCUSSION
In small peripheral lung tumors with no lymphadenopa-
thy, a negative mediastinal PET or PET/CT scan may be
helpful in guiding a selective approach to mediastinoscopy.
The probability that such patients have mediastinal lymph
node metastases is low.2 On the other hand, PET scanning
has a significant rate of false-positive results for mediastinal
lymph node metastases in patients with lung cancer.3 There-
fore, it may be best to confirm positive mediastinal PET find-
ings with a lymph node biopsy. This course of action should
minimize stage misclassification and ensure that surgical
candidates are not denied potentially curative resection. In
patients with a positive mediastinal PET scan, EBUS may
be helpful in determining whether lymph nodes are truly in-
volved with cancer. If the EBUS-TBNA is positive for can-
cer, mediastinoscopy may not be necessary as illustrated in
Figure 1. Our preliminary experience seems to support the
use of EBUS-TBNA as complementary to mediastinoscopy
in obtaining diagnostic tissue from mediastinal lymph no-
des. Some investigators may be of the opinion that EBUS,
in combination with endoscopic esophageal ultrasound,
may eventually render mediastinoscopy obsolete.4 They
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Smay quote that as many as 54.4% of mediastinoscopies
yield no lymphoid tissue on final pathology.5 However,
this seemingly high proportion would be more accurately in-
terpreted in light of the qualifications of the surgeons
performing mediastinoscopy. Unfortunately, this informa-
tion is not available. The yield of mediastinoscopy seems
to be substantially higher in large case series (ie,>3000 pa-
tients) published by thoracic surgeons.6,7
The probability of a false-negative frozen section or final
pathology result after mediastinoscopy is reportedly low
(0.6%–8.8%).6,8 Therefore, it is considered acceptable to
perform mediastinoscopy either as a stand-alone procedure
or in combination with pulmonary resection. To evaluate
EBUS-TBNA as an intraoperative decision-making tool,
we reviewed our ROSE results. The purpose of ROSE is
to minimize inadequate specimens and improve diagnostic
yield. In this study, the proportion of nondiagnostic ROSE
results was higher than previously published rates after
TBNA (31.1% vs 3.3%–17.8%).9,10 However, this may
be related in part to the relatively lower prevalence of cancer
in our study population (44% vs 66–71.6%). On the basis of
our results and other reports, we have decided not to use in-
traoperative (ie, ROSE) EBUS-TBNA results to decide
whether it is indicated to proceed with lung resection.
The final cytology report is usually available within a few
days of the procedure. In previously published larger (ie,
n>100) EBUS case series, the sensitivity, specificity, pos-
itive predictive values, and negative predictive values were
92.3% to 94.6%, 100%, 100%, and 11% to 97.4%,
respectively.11-13 Although only a subset of our patients
(66.6%) had pathologic testing in addition to EBUS cytol-
ogy, we found this proportion to be comparable to published
literature (6%–100%).11-13 Although in our study popula-
tion, the specificity (100%) was similar to published data,
the sensitivity (85%) was slightly lower. The diagnostic
yield of cytology was also lower in our study (74.3% vs
93.5%–100%).11-13 Once again, the lower sensitivity and
diagnostic accuracy in our study group may be due to differ-
ences in disease prevalence between study populations
(44% vs 25.5%–100%). Other potential factors (ie, opera-
tor, number of cases, diagnosis, indication, preoperative im-
aging, and number of stations sampled) did not have
a significant influence on diagnostic accuracy.
We realize that the results must be interpreted in light of
the limitations inherent to a retrospective study design. We
also acknowledge that generalizations regarding diagnostic
performance may be limited by the need for subset analysis.
Because this was not a prospective research protocol, media-
stinoscopy was performed when judged clinically appropri-
ate. At this point in our experience, the results lend support
to the use of mediastinoscopy when EBUS-TBNA is nega-
tive or nondiagnostic. In selected patients where the cytol-
ogy is positive for cancer, a specific benign diagnosis is
obtained, the operator is confident that the scope was posi-
tioned accurately, and the needle puncture sites are in the
correct anatomic location, it may be reasonable to forego
mediastinoscopy. The relationship between EBUS and
mediastinoscopy will likely be refined once more data are
available.
CONCLUSIONS
Our results have guided the design of a clinical pathway
for the use of EBUS in the evaluation of patients with abnor-
mal mediastinal lymph nodes on CT or PET scan (Figure 1).
Acquired experience with EBUS provides preliminary data
and mitigates the potential negative effects of procedural
training and learning curve on diagnostic performance. Al-
though the actual needle sampling technique is relatively
easy to master, it is our impression that a significant period
of adaptation and learning is necessary to understand endo-
bronchial ultrasonography of the mediastinum. The ultra-
sound image is dynamic rather than static and often
presents anatomic relationships in planes that are different
from standard CT scanning. Because of operative experi-
ence, the thoracic surgeon may be in a favorable position
to understand the anatomic relationships displayed during
EBUS. Although major societies have recommended at least
40 to 50 supervised procedures to establish basic EBUS
competency, this requirement may be less for surgeons
who routinely perform bronchoscopy and mediastinal
FIGURE 1. Diagnostic approach to the patient with suspected malignant
mediastinal lymphadenopathy. CT, Computed tomography; PET, positron
emission tomography; LN, lymph node; EBUS, endobronchial ultrasound.
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Sprocedures.14,15 Emerging minimally invasive diagnostic
modalities will continue to challenge established ap-
proaches. To remain at the forefront of the diagnosis, stag-
ing, and management of lung cancer, surgeons should
invest the time and effort necessary to evaluate new technol-
ogy firsthand.
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Discussion
Dr S. Swisher (Houston, Tex). Endobronchial ultrasonography
is a novel minimally invasive technology that allows diagnosis and
staging of mediastinal nodes through ultrasound-guided fine-nee-
dle aspiration. Dr Gilbert and colleagues are to be commended
for rapidly incorporating this new technology into the thoracic sur-
geon’s armamentarium and reviewing their preliminary results. It is
critical to our profession that thoracic surgeons remain at the van-
guard in learning this technique and assessing its strengths and
weaknesses compared with other standard techniques, such as me-
diastinoscopy, so that as a profession, we remain included in the
process of evaluating and staging lung cancer in patients.
My first questions revolve around diagnostic accuracy. Seventy-
five patients were reviewed in this series for a variety of reasons,
including diagnosis of malignancy and staging of lung cancer.
The authors found that rapid on-site assessment was diagnostic
only 69% of the time, whereas final cytologic evaluation was diag-
nostic 74% of the time. The authors could not identify any factors
that were associated with improved diagnostic accuracy, including
operator experience or number of lymph node stations sampled. In
most series the diagnostic yield is higher than what the authors re-
port here. How do the authors explain their diagnostic yield of
74%?
Most studies have also demonstrated that the number of aspira-
tions of each nodal station correlates with accuracy. How many
passes were performed in this study at each nodal station, and could
this have influenced diagnostic yield?
Lymph node size has also been found to correlate with diagnos-
tic yield in several studies. Did the authors evaluate lymph node
size with respect to the sampling accuracy, and did this correlate
with diagnostic yield?
Finally, of note, 56% of the patients in this study had only 1
nodal station sampled. Why did the authors not sample more lymph
nodes stations? Was it not possible in some of these patients?
Dr Gilbert. I will attempt to answer all of your pertinent ques-
tions in the sequence they were posed. The diagnostic yield of
EBUS can be influenced significantly by the definition of a ‘‘diag-
nostic sample’’ and the prevalence of cancer in the population stud-
ied. We have used stringent definitions of what is considered
‘‘diagnostic’’ when compared with other published series of
EBUS. For instance, specimens interpreted as ‘‘suspicious for ma-
lignancy’’ or ‘‘atypical cells present’’ were not considered diagnos-
tic because, in our opinion, clinical decisions cannot be safely based
on such results.
The setting of your EBUS review can be used as an example to
illustrate my second point regarding diagnostic yield. If a study of
EBUS is carried out in a large cancer center, it is possible that a sig-
nificant proportion of the patients will have mediastinal adenopathy
of malignant cause. The nature of the cancer center’s referral pat-
tern would likely bias the study population in that manner. When
using a highly specific diagnostic test, such as EBUS-TBNA, the
diagnostic yield will automatically appear better in study popula-
tions with higher cancer prevalence. This epidemiologic phenome-
non alone will result in improved diagnostic yield regardless of
other factors (eg, lymph node size, number of needle passes, oper-
ator experience, and cytology expertise). The prevalence of cancer
in our study was relatively low compared with other series, and this
probably had an impact on our diagnostic yield. The diagnostic per-
formance of EBUS at our institution is actually comparable to re-
sults previously published in the Journal of the American
Medical Association by Dr Wallace et al from the Mayo Clinic.
In the hands of these investigators, EBUS-TBNA alone had a lower
sensitivity, specificity, and positive predictive value and a higher
false-negative rate than what we have obtained in our initial expe-
rience. Because the prevalence of cancer in their study group and
ours was similar, the diagnostic performance parameters should
be comparable.
With regard to the number of needle passes per lymph nodes, we
did not look at this data specifically. We routinely use 3 passes per
lymph node unless a positive cancer diagnosis is obtained with
a lesser number of passes. In general, if the rapid on-site cytologic
evaluation remains nondiagnostic after 3 to 4 needle passes, we
move on to the next lymph node station to be sampled or perform
a mediastinoscopy when appropriate.
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ing lymph nodes smaller or equal to 1 cm in their shortest axis or
larger than 1 cm. There was no difference in diagnostic yield be-
tween those 2 subgroups.
You also asked why 56% of the patients did not have multi-
station sampling as is routinely done during mediastinoscopy.
Our study sample included a heterogenous group of patients
thought to be reflective of general thoracic surgery practice. For in-
stance, we evaluated patients with a suspected recurrent cancer in
a single abnormal mediastinal or hilar lymph node station on imag-
ing, patients who were eventually diagnosed with small cell lung
cancer, metastatic cancer, or sarcoidosis after the first station sam-
pled, and patients with N3 disease. These clinical situations do not
always require multiple stations to be sampled in order to obtain
a diagnosis and stage, and to devise a treatment plan. In patients
where the mediastinum is staged in preparation for lung resection,
our approach is to evaluate bilateral paratracheal and subcarinal sta-
tions beginning with the N3 lymph node stations.
Dr Swisher. My second question revolves around the impor-
tance of using EBUS and pathologic staging to assess PET-positive
mediastinal nodes. We are in an era similar to before when CT in-
crease in size of greater than 1 cm was taken by the oncologist to
mean positive nodes, often without pathology. Now we are doing
the same thing with new technology, and it’s critical that we can
pathologically evaluate this. EBUS may be an avenue to allow
pathologic confirmation. In the present series, diagnostic accuracy
was only 67%, with 29 of 43 PET-positive cases. In the 14 cases in
which EBUS was nondiagnostic, was the node in question visual-
ized and accessible by EBUS? Were these nodes in regions that
would have been accessible by mediastinoscopy, or were they in
the hilar or anteroposterior window regions?
Dr Gilbert. Four of these patients had a previous lung resection
for lung cancer. Two underwent mediastinoscopy which was neg-
ative and 1 had a percutaneous fine-needle aspiration of a right par-
atracheal node which was positive for recurrent cancer. The fourth
patient’s follow-up PET scan showed resolution of the mediastinal
FDG uptake and he was obsereved. Four additional patients had
abnormal lymph node stations not accessible by mediastinoscopy.
The remaining 6 patients had PET-positive mediastinal lymph
nodes. Three underwent mediastinoscopy and it was positive for
cancer in 2 and negative in 1. The latter patient had an EBUS-
TBNA which was suspicious for lymphoma. The fourth patient
had transbronchial biopsy of his lung mass which showed necrotiz-
ing granulomata. This type of biopsy was not considered an accept-
able reference standard for EBUS as stated in our methods. The fifth
patient had lung cancer and had previously received thoracic radio-
theraphy. He was deemed a non-surgical candidate and declined to
have more invasive diagnostic procedures performed. The last pa-
tient had a MRI scan for shoulder symptoms which revealed a scap-
ular metastasis. He did not require any further mediastinal workup.
Dr Patterson. Let me just interrupt. In the interest of time, can
we have minimal commentary and maximal short questions be-
cause we have a couple of other discussants who want to ask
some questions.
Dr Swisher. Thank you for bringing these preliminary results to
the forefront of our group.
Dr Gilbert. Thank you, Sir.
Dr R. Cerfolio (Birmingham, Ala). What was considered a pos-
itive PET? Did you use an absolute value of the node, ratio of the
node to the primary tumor?
Dr Gilbert. Given the retrospective study design, the radiology
reports were reviewed to determine whether or not a given site was
positive or negative on PET. Standard uptake values are not always
reported at our institution. From my discussions with nuclear med-
icine specialists and radiologists, a baseline level of FDG uptake is
usually established, using the liver parenchyma for instance, and
abnormal levels of FDG avidity are established in relationship to
that baseline in each patient.
Dr Cerfolio. Okay—not ideal, was it. My second question is
about the logistics and the politics. To keep everybody happy,
the surgeons, pulmonologists, and pulmonary fellows, how are
you doing it so the pulmonary fellows can come through to keep
the pulmonologists happy, because they also control our volume,
and the cardiothoracic fellows; how are you doing it at your insti-
tution to keep everybody happy?
Dr Gilbert. For those who wish to use the EBUS scopes ac-
quired by the operating room, we have established basic credential-
ing requirements, which include completion of an off-site EBUS
course and at least 5 on-site proctored cases. In our group, there
is a pulmonologist who performs and teaches the procedure rou-
tinely. I believe that people who share a common interest in the di-
agnosis and treatment of lung cancer and mediastinal disease should
consider learning the technique, regardless of their specialty.
Dr A. Vaporciyan (Houston, Tex). We have struggled with how
many proctored EBUSs are required before one is considered
trained in this. Obviously everybody has different definitions.
Where did you come up with 5 proctored EBUSs to consider your-
self trained in it? Was it from literature or your experience?
Dr Gilbert. It is an institution-specific policy which was estab-
lished after discussion with the departmental chair. The literature
suggest that 30-50 supervised procedures may be needed for pulmo-
nologists to establish proficiency. This number may be lower for
thoracic surgeons given their clinical training and operative experi-
ence with lung cancer and mediastinal diseases.418 The Journal of Thoracic and Cardiovascular Surgery c February 2009
